Neurocrine Biosciences
NBIX
345 hedge funds and large institutions have $10.9B invested in Neurocrine Biosciences in 2018 Q3 according to their latest regulatory filings, with 90 funds opening new positions, 94 increasing their positions, 115 reducing their positions, and 17 closing their positions.
429% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 17
26% more funds holding
Funds holding: 274 → 345 (+71)
21% more capital invested
Capital invested by funds: $9.03B → $10.9B (+$1.87B)
4.22% less ownership
Funds ownership: 102.23% → 98% (-4.2%)
18% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 115
28% less call options, than puts
Call options by funds: $60.8M | Put options by funds: $84.1M
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$37.6M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$30.8M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$30.1M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$29.3M |
| 5 |
Two Sigma Advisers
New York
|
+$27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$148M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$94.3M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$59.6M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$55.7M |
| 5 |
HM
HealthCor Management
New York
|
-$43.5M |
NBIX Hedge Fund Activity: Q3 2018 in Review
345 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2018, worth a combined $10.9B — up 21% from $9.03B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new NBIX positions and 17 closed out — a net gain of 73 holders — while 94 added to existing stakes and 115 trimmed.
The largest buyer was Millennium Management, adding an estimated $37.6M. The largest seller was Wellington Management Group, cutting an estimated $148M.
- 345 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2018, up from 274 in Q2 2018.
- Funds reported $10.9B of Neurocrine Biosciences stock for Q3 2018, up 21% quarter-over-quarter.
- 90 funds opened new Neurocrine Biosciences positions in Q3 2018 and 17 closed out, a net change of +73 holders.
- The largest Neurocrine Biosciences buyer in Q3 2018 was Millennium Management, an estimated $37.6M added.
- The largest Neurocrine Biosciences seller in Q3 2018 was Wellington Management Group, an estimated $148M sold.
Based on aggregated 13F filings for Q3 2018.